Addenda to the Depot buprenorphine clinical guidelines are proposed to and agreed upon by the Depot Buprenorphine Working Group, made up of experienced clinicians, a consumer representative , and NSW Health.
The following is to be read on page 15 under ii. contraindications:
- Buvidal® Weekly or Buvidal® Monthly should not be administered to anyone hypersensitive to BPN (see below) or any of the excipients [phosphatidyl choline [soybean], glyceryl dioleate and ethanol anhydrous (in Buvidal® Weekly), and N-methyl-2- pyrrolidone (in Buvidal® Monthly)].
- Sublocade® should not be administered to patients who have been shown to be hypersensitive (see below) to BPN or any component of the ATRIGEL® delivery system [i.e. N-methyl-2- pyrrolidone (NMP) and Poly (DL-lactide-co-glycolide) (PLGA/polyglactin)].
- The features of hypersensitivity to BPN include rashes, hives, and pruritis. Most serious reported cases have involved bronchospasm, angioneurotic oedema, and anaphylactic shock. It should be noted that hypersensitivity to buprenorphine, and anaphylaxis to depot buprenorphine is very rare. However, all sites that administer depot buprenorphine should have anaphylaxis response procedures in place when giving depot injections.
The following addendum is to be read at the bottom of page 40
, in the section on hospital and correctional settings: